SCHEMBL6434069

SCHEMBL6434069

CC(C)(C)OC(=O)Nc1cc(Cl)c(C(F)(F)F)cc1NC(=O)CC(=O)c1cccc(-n2ccnc2)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 1/20 0.44
L3MBTL1 Q9Y468 3/20 0.40
MEN1 O00255 1/20 0.37
ALDH1A1 P00352 1/20 0.37
KMT2A Q03164 1/20 0.37
IDO1 P14902 1/20 0.37
F9 P00740 1/20 0.37
F10 P00742 1/20 0.37
PDE4A P27815 1/20 0.37
PDE4B Q07343 1/20 0.37
PDE4C Q08493 1/20 0.37
PDE4D Q08499 1/20 0.37
KDM4D Q6B0I6 1/20 0.36
POLB P06746 1/20 0.36
GPR119 Q8TDV5 1/20 0.36
LMNA P02545 1/20 0.36
MAPT P10636 1/20 0.36
ADH5 P11766 1/20 0.35
GPR142 Q7Z601 1/20 0.35
BRD4 O60885 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6433115 0.91 ABL1 (0.45) ABL1L3MBTL1F9F10PDE4A
SCHEMBL7220987 0.89 ABL1 (0.43) ABL1L3MBTL1F9F10PDE4A
SCHEMBL6164710 0.87 ABL1 (0.41) ABL1L3MBTL1ALDH1A1F9F10
SCHEMBL6437848 0.86 NOTUM (0.43) L3MBTL1MEN1ALDH1A1KMT2APOLB
SCHEMBL7143394 0.86 ADH5 (0.40) ABL1L3MBTL1IDO1PDE4APDE4B
SCHEMBL6438740 0.85 RAB9A (0.38) L3MBTL1MEN1ALDH1A1KMT2APOLB
SCHEMBL6165695 0.85 ABL1 (0.39) ABL1L3MBTL1KMT2AIDO1PDE4A
SCHEMBL6434658 0.84 L3MBTL1 (0.45) ABL1L3MBTL1ALDH1A1PDE4APDE4B
SCHEMBL5559923 0.82 CYP17A1 (0.44) ABL1MEN1ALDH1A1KMT2APOLB
SCHEMBL5564494 0.82 CYP17A1 (0.44) ABL1MEN1ALDH1A1KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1379522-B1 DIHYDRO-BENZO(b)(1,4)DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS I HOFFMANN LA ROCHE (CH) 2005-01-26 EP disclosed
EP-1379522-A1 DIHYDRO-BENZO(b)(1,4)DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS I F. HOFFMANN-LA ROCHE AG (CH) 2004-01-14 EP disclosed
US-6548495-B2 Metabotropic glutamate receptor agonist for treatment or prevention of acute and/or chronic neurological disorders HOFFMANN-LA ROCHE INC. 2003-04-15 US disclosed
US-20020198197-A1 Dihydro-benzo [b] [1,4] diazepin-2-one derivatives HOFFMANN-LA ROCHE INC. 2002-12-26 US disclosed
WO-2002083665-A1 DIHYDRO-BENZO[b][1,4]DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS I F. HOFFMANN-LA ROCHE AG (CH) 2002-10-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020198197-A1 Dihydro-benzo [b] [1,4] diazepin-2-one derivatives BDKRB1, BDKRB2, GRIN1 ABL1 2651/4885L3MBTL1 3136/4885MEN1 1315/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.